SCHEMBL13899433

SCHEMBL13899433

CC(C)(Oc1ccc(SC(CCC(F)(F)F)c2nnc(-c3ccc(C(F)(F)F)cc3)o2)cc1)C(=O)O

nearest known ligand 0.44

Predicted protein targets (top 4)

geneUniProtsupporting neighboursconfidence
PPARA Q07869 17/20 0.44
PPARD Q03181 14/20 0.44
PPARG P37231 8/20 0.44
TP53 P04637 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13899447 0.91 PPARA (0.43) PPARAPPARDPPARG
SCHEMBL13899432 0.84 PPARA (0.46) PPARAPPARDPPARG
SCHEMBL13899240 0.78 PPARA (0.45) PPARAPPARDPPARG
SCHEMBL13899434 0.78 PPARA (0.45) PPARAPPARDPPARG
SCHEMBL13899480 0.77 PPARD (0.50) PPARAPPARDPPARG
SCHEMBL13899214 0.76 PPARA (0.48) PPARAPPARDPPARG
SCHEMBL13899451 0.75 PPARA (0.46) PPARAPPARDPPARG
SCHEMBL13899466 0.71 PPARA (0.62) PPARAPPARDPPARG
SCHEMBL13899364 0.71 PPARD (0.51) PPARAPPARDPPARG
SCHEMBL13899379 0.71 PPARD (0.51) PPARAPPARDPPARG

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7507832-B2 Triazole PPAR modulators ELI LILLY AND COMPANY (US) 2009-03-24 US disclosed
US-7507832-B2 Triazole PPAR modulators ELI LILLY AND COMPANY (US) 2009-03-24 US disclosed
US-20070112045-A1 Triazole ppar modulators ELI LILLY AND COMPANY 2007-05-17 US disclosed
US-20070112045-A1 Triazole ppar modulators ELI LILLY AND COMPANY 2007-05-17 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070112045-A1 Triazole ppar modulators PPARD, PPARA, PPARG PPARA 2/4885PPARD 1/4885PPARG 3/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.